UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
CYTOF holding history
Altamira Therapeutics Ltd. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CYTOF overviewAll 13F holders of CYTOFFull Q2 2026 holdings
- Shares (Q3 2024)
- 0
- Sold out in Q3 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2024 | 0 | $0 | 0.0% | −1,711−100.0% | Sold out | Holders |
| Q2 2024 | 1,711 | $1.90K | <0.1% | +1,711 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −6,814−100.0% | Sold out | Holders |
| Q4 2023 | 6,814 | $23.7K | <0.1% | +6,814 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −1,532−100.0% | Sold out | Holders |
| Q1 2023 | 1,532 | $1.96K | <0.1% | −2,315−60.2% | Reduced | Holders |
| Q4 2022 | 3,847 | $18.7K | <0.1% | −4,286−52.7% | Reduced | Holders |
| Q3 2022 | 8,133 | $2.00K | <0.1% | −17,941−68.8% | Reduced | Holders |
| Q2 2022 | 26,074 | $13.0K | <0.1% | +22,588+648.0% | Added | Holders |
| Q1 2022 | 3,486 | $4.00K | <0.1% | −3,869−52.6% | Reduced | Holders |
| Q4 2021 | 7,355 | $13.0K | <0.1% | +3,432+87.5% | Added | Holders |
| Q3 2021 | 3,923 | $8.00K | <0.1% | +3,923 | New | Holders |